The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Grant Support/Research Contract - Abbott; Sahajanand Medical Technologies Ltd.
- Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Terumo Medical Corporation; Microport
- Equity/Stock(s)/Options - CERC